Incorporating apoB into the assessment of traditional modifiable risk factors elucidated part of the previously residual 20‐year ASCVD risk, suggesting ApoB may be a superior biomarker for assessing long‐term ASCVD risk. The gene discussed is APOB; the disease is atherosclerosis.